Saturday 17 October 2026
Export SPRO’s income statement to Excel — free account
Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
1.10
0.03
−2.65%
Follow SPRO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 8.67 | 15.53 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 2.19 | 1.95 | 2.61 | |
P/FCF ratio |
— | 18.61 | 0.00 | 0.00 | |
P/Operating CF |
— | 8.45 | (15.63) | 6.07 | |
P/B ratio |
— | 2.53 | 2.21 | 3.99 | |
Price to Tangible BV |
— | 2.53 | 2.21 | 3.99 | |
EV/Sales |
— | 1.27 | 1.35 | 1.41 | |
EV/EBITDA |
— | 5.77 | 14.30 | 0.00 | |
EV/Operating CF |
— | 10.76 | (7.15) | (2.07) | |
EV/FCF |
— | 10.82 | (7.13) | (2.06) | |
Quick Ratio |
6.03 | 10.23 | 7.40 | 3.74 | |
Current Ratio |
6.12 | 10.50 | 7.59 | 3.83 | |
Net Debt/EBITDA |
5.12 | 7.45 | (1.28) | 6.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.90 | 0.74 | 0.43 | |
Operating CF/Net income |
0.56 | (2.20) | (0.26) | (2.36) | |
Research and Development Expense of Revenue |
0.00% | 1,127.52% | 13.54% | 157.98% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,894.19% | 10.41% | 76.70% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 431.78% | 2.44% | 19.26% | |
Graham Net Nets |
— | 0.38 | 0.44 | 0.23 | |
Graham Number |
— | 2.37 | 1.89 | 0.00 | |
Earnings Yield |
— | 11.54% | 6.44% | (42.02%) | |
Free Cash Flow Yield |
— | 5.37% | (9.70%) | (26.19%) | |
Revenue per Share |
0.00 | 0.00 | 0.74 | 0.10 | |
Operating CF per Share |
(0.09) | 0.28 | (0.15) | 0.31 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | 0.28 | (0.15) | 0.31 | |
Cash per Share |
0.88 | 0.98 | 0.72 | 0.86 | |
Shareholders Equity per Share |
0.76 | 0.92 | 1.05 | 0.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.76 | 0.92 | 1.05 | 0.47 | |
Free Cash Flow |
(5.35) | 15.86 | (8.35) | 17.42 | |
Working Capital |
43.16 | 52.12 | 58.42 | 38.67 | |
Net Current Asset Value |
43.02 | 51.53 | 57.39 | 24.65 | |
EV/EBIT |
— | 5.77 | 14.30 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 9.92 | 20.67 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.47 | 12.16 | 38.93 | 27.87 | |
Average Payables |
0.47 | 0.99 | 4.00 | 3.74 | |
Average Assets |
57.44 | 68.37 | 89.73 | 94.67 | |
Average Common Equity |
38.52 | 43.37 | 52.57 | 46.00 |
Columns are period end dates